Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...
Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
Researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery. Our immune system is armed with an array of defenses designed to detect and ...
An international research group directed by UMC Utrecht has developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI. Their findings open ...
SAN DIEGO -- Kidney transplant patients who shifted into newly recognized microvascular inflammation categories under revised definitions had an intermediate risk of poor allograft outcomes, a large ...
Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...
In a landmark study analyzing more than 16,000 biopsies from almost 7,000 kidney transplant recipients, researchers found that many cases initially considered as non-rejection were reclassified into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback